Daiichi Sankyō
| Daiichi Sankyō KK
|
|
|---|---|
 |
|
| legal form | Kabushiki kaisha |
| ISIN | JP3475350009 |
| founding | September 28, 2005 (as KK), company founded in 1899. |
| Seat |
Tokyo , Japan
|
| management | Joji Nakayama |
| Number of employees | 16,428 (2015) |
| sales | JPY 919.4 billion (2014/15) EUR 7.13 billion |
| Branch | Pharmaceutical company |
| Website | www.daiichi-sankyo.co.jp |
Daiichi Sankyō KK ( Japanese 第一 三 共 株式会社 , Daiichi Sankyō Kabushiki kaisha , English Daiichi Sankyo Co., Ltd. ) is a Japanese global research-based pharmaceutical company, it is listed in the Nikkei 225 .
The corporate headquarters are in Tokyo . Founded in 1899, Daiichi Sankyō has been researching, developing and producing innovative medicines since the dawn of industrial drug manufacturing. The European headquarters, Daiichi Sankyo Europe GmbH, and the German subsidiary, Daiichi Sankyo Deutschland GmbH, are both located in Munich . In Europe, Daiichi Sankyō currently has 12 country offices and employs over 2,500 people there, almost 1,500 of them in the field.
history
Daiichi Sankyō KK was founded as a joint holding company by the two Japanese pharmaceutical companies Sankyō KK ( 三 共 株式会社 , English Sankyo Co., Ltd. ) and Daiichi Seiyaku KK ( 第一 製 薬 株式会社 , English Daiichi Pharmaceutical Co., Ltd. ) founded on September 28, 2005.
Ranbaxy Laboratories , India's largest pharmaceutical company, became part of the group in November 2008. In the ranking of the leading pharmaceutical companies in the world, Daichi Sankyō is among the top 20. In Japan, Daichi Sankyō is one of the top 3 pharmaceutical companies.
In 2009, the agrochemicals division of Sankyō was taken over by Mitsui Chemicals .
The European roots of the group go back to 1910. The company is currently present in twelve European countries; these include Germany, Great Britain, France, Italy and Spain, the most important European pharmaceutical markets.
In early March 2011, the Japanese parent company announced that it would take over Plexxikon for around 800 million US dollars. Plexxikon Inc. is a Berkeley, California-based pharmaceutical company specializing in the development of oncological drugs. The most promising candidate is vemurafenib , previously developed together with Roche , for the treatment of metastatic skin cancer.
Most famous medicines of the Daiichi Sankyō group
- Efient ( Prasugrel )
- Olmetec ( olmesartan )
- Olmetec Plus (olmesartan and hydrochlorothiazide )
- Evista ( raloxifene )
- Sevikar (olmesartan and amlodipine )
- Sevikar HCT (olmesartan medoxomil, amlodipine and hydrochlorothiazide)
- Orelox (cefpodoxime proxetil)
- Combizym ( Aspergillus oryzae enzyme mixture / pancreas powder)
- Mevalotin ( pravastatin )
- Loxonin ( Loxoprofen )
- Captopril
- Zantac ( ranitidine )
- WelChol ( Colesevelam )
- Cravit ( Levofloxacin )
- Evoxac ( cevimeline )
- FloxinOtic ( Ofloxacin )
- Lopresor ( metoprolol )
- Lomir / Icaz ( Isradipine )
- Luivac
- Benicar ( Olmesartan )
- Mobilat ( chondroitin , salicylic acid ), one of the best-known medicines for pain in the muscles and joints, was sold to the German generic drug manufacturer STADA in 2005 .
- Lixiana ( Edoxaban )
Web links
Individual evidence
- ↑ a b Daiichi Sankyo 2015 Annual Report , accessed May 13, 2016
- ↑ Converted at the rate on the balance sheet date, March 31, 2015
- ↑ Mitsui Chemicals, Inc. will split its Agrochemicals Division and Integrate it with Sankyo Agro Co., Ltd. dated January 30, 2009.
- ↑ Vemurafenib New Drug Application Submitted to FDA for Melanoma. ( Memento of November 7, 2011 in the Internet Archive ) Press release of May 11, 2011.
- ↑ STADA: Product acquisitions (including Mobilat®) strengthen branded business in Europe (ad hoc announcement according to Section 15 WpHG) stada.de. December 12, 2005. Retrieved July 7, 2012.